Peetz Christopher exercised Options for 30,000 Mirum Pharmaceuticals shares and sold 30,000 shares on 2026-09-01. The reported transactions leave him with 194,440 shares and 58,487 derivative securities, while the exercise and sales carry separately stated per-share prices for investors assessing insider ownership.
Key Highlights
- The option exercise was priced at $2.94 per share.
- The two share-sale transactions ranged from $98.08 to $98.91 per share.
- Christopher’s reported derivative securities ownership stood at 58,487 after the exercise.
Peetz Christopher exercised options for 30,000 Mirum Pharmaceuticals (NASDAQ: MIRM) shares and sold 30,000 shares on 1 September 2026.
Mirum Share Ownership Recorded After Transactions
Christopher’s option exercise left his reported common-share ownership at 224,440 shares before the subsequent sales. The 30,000-share disposal was completed through two separate transactions. Sale prices ranged from $98.08 to $98.91 per share. A separate option exercise involving 30,000 derivative securities left him with 58,487 derivative securities.
Exercise and Sale Prices Show Separate Per-Share Amounts
The exercise price was $2.94 per share, while the sales were executed within the $98.08 to $98.91 per-share range. The filing separately reports the $2.94 exercise price and the $98.08 to $98.91 sales range on 1 September 2026. Following the sales, Christopher’s reported ownership was 194,440 Mirum Pharmaceuticals shares.
FAQs
Q: What did Peetz Christopher do with Mirum Pharmaceuticals shares?
A: On 1 September 2026, Peetz Christopher exercised options for 30,000 Mirum Pharmaceuticals shares. He also sold 30,000 shares in two separate transactions reported under SEC transaction code S.
Q: What price did Peetz Christopher receive for the Mirum share sales?
A: The two Mirum Pharmaceuticals share-sale transactions were reported at prices ranging from $98.08 to $98.91 per share. Both sales occurred on 1 September 2026.
Q: How many Mirum shares and derivatives did Christopher own afterward?
A: Following the reported share sales, Christopher owned 194,440 Mirum Pharmaceuticals shares. The filing also reported that he owned 58,487 derivative securities after exercising options for 30,000 derivative securities.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.